Key result
Unstable carotid plaques show ~18-fold higher IL-36β expression vs. stable lesions, especially in diabetes.
Why the study?
Members of the interleukin-1 family—particularly IL-36, IL-37, and IL-38—are implicated in inflammatory vascular disease, but their roles in carotid atherosclerosis and diabetic plaque instability remained poorly defined.
Does type 2 diabetes mellitus alter circulating levels and local carotid plaque expression of IL-36, IL-37, and IL-38 cytokines in relation to carotid plaque stability?
Observational (n=110)
Yes
Does type 2 diabetes mellitus alter circulating levels and local carotid plaque expression of IL-36, IL-37, and IL-38 cytokines in relation to carotid plaque stability?
Answers are grounded in this paper and cite their sources.
This study identifies marked local upregulation of IL-36, IL-37, and IL-38—particularly a >25-fold increase in pro-inflammatory IL-36β—exclusively within unstable carotid plaques of diabetic patients, highlighting IL-36β as a potential therapeutic target for diabetic plaque vulnerability.
Background: Type 2 diabetes mellitus (T2DM) promotes atherosclerosis and plaque instability through chronic inflammation and immune dysregulation. Emerging evidence implicates members of the interleukin-1 family-particularly IL-36, IL-37, and IL-38-in the modulation of inflammatory responses in diabetic and non-diabetic vascular disease. However, their roles in carotid atherosclerosis remain poorly defined. Methods: In this retrospective observational study, circulating cytokine levels were assessed in 20 T2DM and 40 non-DM individuals using ELISA. Carotid plaque samples (n = 50) were collected from endarterectomy procedures and categorised as stable (asymptomatic, n = 25) or unstable (symptomatic, n = 25) according to AHA criteria. Immunohistochemistry quantified local expression of IL-36α, IL-36β, IL-36γ, IL-37, and IL-38. Results: Circulating IL-36α, IL-36β and IL-36γ were significantly elevated in T2DM patients, while IL-37 and IL-38 levels were unchanged. Immunohistochemistry revealed significantly increased expression of all five cytokines in unstable versus stable plaques. Stratification by diabetic status showed that this upregulation was exclusive to diabetic patients. Notably, IL-36β exhibited the most pronounced increase-over 25-fold-in unstable diabetic plaques. IL-37 and IL-38 were also elevated locally, likely reflecting compensatory anti-inflammatory responses, though their circulating levels remained unaffected. Conclusions: This study demonstrates differential expression of IL-36, IL-37, and IL-38 in carotid atherosclerotic plaques, with IL-36β emerging as a key pro-atherogenic cytokine in the diabetic setting. The distinct expression patterns of these cytokines in diabetic versus non-diabetic plaques suggest that T2DM exacerbates immune imbalance in atherosclerosis. These findings may inform future research on cytokine-targeted therapies for diabetic vascular complications.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2025) conducted an observational in Type 2 diabetes mellitus and carotid artery disease (n=110). Type 2 diabetes mellitus and symptomatic unstable carotid plaque status vs. Non-diabetic status and asymptomatic stable carotid plaque status was evaluated on Local carotid plaque expression of IL-36β (arbitrary units) in unstable vs stable plaques (p=0.0314). Unstable carotid plaques exhibited over 20-fold higher IL-36β expression than stable plaques, driven by a >25-fold increase in diabetic unstable plaques.
Synapse has enriched 10 related papers. Consider them for comparative context: